UAE – Bioventure Healthcare, a biopharmaceutical company based in the United Arab Emirates, has signed a pharmaceutical partnership agreement with EZulu Life.
EZulu Life is a multinational medical technology and nutraceutical company headquartered in the Republic of South Africa, with a market capitalisation of US$100 million.
In an official statement, the company said: “EZulu Life has been selected to distribute Bioventure Healthcare’s products and provide technical support in the Southern and East African regions.”
The new agreement reinforces Bioventure Healthcare’s presence in Africa as it prepares to export four products and brands to key markets on the continent.
Bioventure is the investment arm of GlobalOne Healthcare Holding, a prominent investment and business development organization that operates within the healthcare industry in the UAE and internationally.
GlobalOne Healthcare is dedicated to providing comprehensive healthcare solutions that include fully integrated pharmaceuticals, manufacturing, distribution, health tech, and hospital management.
As part of GlobalOne Healthcare, Bioventure is committed to investing in life science and biotech solutions to promote healthcare innovation and cater to the healthcare needs of patients in the Middle East and Africa.
In addition to enhancing the UAE’s reputation for quality products, Bioventure Healthcare is working closely with EZulu Life to expand its reach in Africa as well as increase trust and brand presence across the region.
This announcement was made during day one of the Dubai Business Forum, which takes place from November 1 to November 2, 2023, on the grounds of Madinat Jumeirah in the emirate of Dubai.
The deal comes shortly after Bioventure Healthcare penned a new manufacturing agreement with GlaxoSmithKline (GSK).
It aligns with Bioventure Healthcare’s mission as a subsidiary of GlobalOne Healthcare to create a market that is attractive for global manufacturing companies and achieve exponential growth in the local health sector.
“With a market capitalisation ranging between US$250 million and US$300 million, Bioventure Healthcare boasts a global distribution network,” the company confirmed in a press statement.
The UAE-based company is committed to investing in life science and biotech solutions to promote innovation in healthcare and cater to the needs of patients in the Middle East and Africa (MEA).
Notably, the partnership agreement between Bioventure Healthcare and EZulu Life was signed at The Deals Hub, part of the Dubai Business Forum, further consolidating Dubai’s position as a leading global city for doing business.
The Deals Hub is a dedicated impact-driven platform for global business leaders and investors to forge and announce major business initiatives, partnerships, investments, and commercial alliances
The Deals Hub is an innovative initiative that reflects Dubai Chambers’ commitment to driving growth in international trade and investment.
It is important to note that Dubai Chambers, a non-profit public entity, supports Dubai’s vision as a global player by empowering businesses, providing innovative value-added services and access to influential networks.
For all the latest healthcare industry news from Africa and the World, subscribe to our NEWSLETTER, and YouTube Channel, follow us on Twitter and LinkedIn, and like us on Facebook.
